UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
Dated: January 23, 2013
Commission File No.000-54749
MORRIA BIOPHARMACEUTICALS PLC
53 Davies Street
London W1K 5JH
United Kingdom
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-Fx Form 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ¨ Nox
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes¨ Nox
Morria Biopharmaceuticals Plc
On January 23, 2013, Morria Biopharmaceuticals Plc (the “Company”) issued a press release announcing that Dr. Alan Harris has joined the Company full time as Chief Medical Officer. Dr. Harris was initially recruited to Morria in July 2012 as Chief Medical Officer in a part-time capacity. He will develop and lead the clinical development programs for Morria’s Multi-Functional Anti-Inflammatory Drug candidates including MRX-4 in allergic rhinitis, and MRX-6 in dermatitis.A copy of the press release is filed as Exhibit 99.1 to this Form 6-K and incorporated by reference herein.
Exhibits
Exhibit Number | | Description of Exhibit |
| 99.1 | | Press Release dated January 23, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | MORRIA BIOPHARMACEUTICALS PLC |
| | By: /s/ Dov Elefant
Dov Elefant
Chief Financial Officer
Date: January 23, 2013 |
